Taking Wegovy with Heart Failure: What the Evidence Says

You've been told you have heart failure, and now you're asking whether Wegovy fits in

Heart failure is one of those diagnoses that arrives differently for different people. Some are told after a scan that their heart muscle is pumping less efficiently than it should (that's heart failure with reduced ejection fraction, HFrEF). Others have a heart that squeezes normally but struggles to relax and fill properly, that's HFpEF. The treatment landscape for the two is quite different, and so is what the semaglutide data actually shows.

For HFpEF specifically, the STEP-HFpEF trial (published in the New England Journal of Medicine, 2023) found that semaglutide 2.4mg produced meaningful reductions in symptoms, physical limitations and body weight compared with placebo in adults with obesity and this subtype of heart failure. That evidence is why clinicians and cardiologists now take the question seriously rather than dismissing it. You can read more about semaglutide's role in heart failure on our dedicated page.

For HFrEF, the position is more cautious. Earlier GLP-1 trial data for this subtype was not encouraging, and current cardiology guidance does not position semaglutide as a treatment here. Weight loss itself may still have indirect benefits, but the evidence does not currently support using Wegovy as a cardiovascular intervention in HFrEF. Your cardiologist will know which camp your diagnosis falls into.

One practical habit worth building before any appointment: check the ejection fraction percentage from your most recent echocardiogram report. It's usually on the first page. If it's above roughly 50%, you likely have HFpEF; below 40% points toward HFrEF. That single number frames the conversation you'll have with your cardiology team.

What Wegovy is actually licensed for, and how cardiovascular protection fits in

Wegovy's primary UK licence covers weight management in adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition. Heart failure, if it's linked to excess weight, can be one of those conditions that makes someone eligible for consideration, though prescriber assessment determines this, not a checklist.

There is a second, separate authorisation. The MHRA has approved semaglutide (Wegovy) for reducing the risk of serious cardiovascular events (heart attack, stroke and cardiovascular death) in adults who already have established cardiovascular disease and a BMI of at least 27. This is based on the SELECT trial data, which showed a roughly 20% relative reduction in those events. The SELECT trial and what it found is worth understanding if cardiovascular protection is part of why you're asking this question.

What this does not mean is that Wegovy is a treatment for heart failure itself in either licence. The distinction matters: being eligible under the cardiovascular-risk licence does not automatically mean heart failure is well-managed or that Wegovy is the right next step for your specific presentation. A prescriber at a service like our Wegovy service will always review your full medical picture, but for anyone with active heart failure, coordination with a cardiologist is essential, not optional.

Practical safety considerations and what to watch for

Assuming your cardiology team agrees that semaglutide is appropriate, a few things are worth knowing from a day-to-day perspective. The most common side effects are gastrointestinal: nausea, loose stools, some vomiting, and reduced appetite, particularly in the first few weeks or after a dose increase. For someone already managing fatigue or fluid retention from heart failure, nausea-driven dehydration is worth flagging early to your care team rather than waiting it out.

People with type 2 diabetes alongside heart failure are in a group where the evidence base is particularly robust. If that describes your situation, Wegovy and type 2 diabetes covers what the trials show. Kidney function is another variable that comes up in heart failure management; Wegovy and kidney disease addresses what prescribers look at in that context.

The MHRA and NHS England both emphasise that GLP-1 medicines should be used as part of a structured plan, not as a standalone fix. The NHS England guidance on weight-management injections outlines the wraparound care that should accompany treatment. That principle applies even more strongly when someone has an active cardiac condition. If you want to understand what a more general assessment for these medicines looks like, our page on semaglutide and heart problems broadly gives more context.

Getting a clinical assessment that accounts for your cardiac history

The path to Wegovy, if it's right for you, starts with a consultation that takes your cardiac diagnosis seriously. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally (the same day) and will look at your full medical history, not just your BMI. If you have active heart failure, our prescribers work within clinical guidelines and will always recommend involving your cardiologist before treatment begins.

You can explore your options and understand how Wegovy is supplied through a regulated UK pharmacy, or review the broader range of weight-loss treatments to understand what might suit your situation. Our clinical team is here to guide that conversation, not to fast-track anyone past it.

If you're ready to discuss your circumstances with a prescriber, start your free consultation, and bring your most recent cardiology letters with you.